Labiana Health SA
MAD:LAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Steve Leung Design Group Ltd
HKEX:2262
|
HK |
|
C
|
Cutia Therapeutics
HKEX:2487
|
CN |
|
B
|
Banco Santander Brasil SA
BOVESPA:SANB3
|
BR |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (3.1), the stock would be worth €4.05 (18% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.7 | €4.92 |
0%
|
| 3-Year Average | 3.1 | €4.05 |
-18%
|
| 5-Year Average | 3.1 | €4.05 |
-18%
|
| Industry Average | 12.9 | €16.91 |
+244%
|
| Country Average | 9.7 | €12.77 |
+159%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
€37.8m
|
/ |
Jul 2025
€10.5m
|
= |
|
|
€37.8m
|
/ |
Dec 2025
€11.3m
|
= |
|
|
€37.8m
|
/ |
Dec 2026
€14.2m
|
= |
|
|
€37.8m
|
/ |
Dec 2027
€17.3m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| ES |
L
|
Labiana Health SA
MAD:LAB
|
41.8m EUR | 3.7 | 46.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 28.7 | 42.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563.9B USD | 17 | 26.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.7 | 19.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.9B GBP | 16.6 | 30 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.7B USD | 9.9 | 16 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228B CHF | 12.5 | 20.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 8.2 | 11.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.7B USD | 7.8 | 20.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.1B USD | 7.2 | 17 |
Market Distribution
| Min | 0 |
| 30th Percentile | 6.5 |
| Median | 9.7 |
| 70th Percentile | 15.3 |
| Max | 700.4 |
Other Multiples
Labiana Health SA
Glance View
Labiana Health SA manufactures sterile and lyophilized dosage forms. The company is headquartered in Pozuelo De Alarcon, Madrid and currently employs 477 full-time employees. The company went IPO on 2022-06-24. The Firm, through its subsidiaries, is engaged in the development, manufacturing and marketing of animal and human medicines. The Company’s main activities are: Drug research and development (R&D), which includes galenic and analytical development; Drug manufacturing, which focuses on formulation development, formulation optimization, bacterial vaccine manufacturing, among others; Regulatory services, which carries out registration procedures for pharmaceutical products in world markets. The Company, through its subsidiaries, is present in Ecuador, Mexico, Serbia and Turkey.
